Aclaris Therapeutics (NASDAQ:ACRS) Sees Strong Trading Volume
Aclaris Therapeutics (NASDAQ:ACRS) Sees Strong Trading Volume
Aclaris Therapeutics, Inc. (NASDAQ:ACRS – Get Rating) shares saw an uptick in trading volume on Friday . 758,008 shares were traded during trading, an increase of 107% from the previous session's volume of 366,400 shares.The stock last traded at $17.30 and had previously closed at $16.82.
Aclaris治療公司(納斯達克代碼：ACRS-GET評級)的股票週五成交量上升。盤中成交量為758,008股，較前一交易日的366,400股增加107%。該股最新報17.30美元，此前收盤報16.82美元。
Analyst Upgrades and Downgrades
分析師升級和下調評級
A number of brokerages recently commented on ACRS. StockNews.com began coverage on Aclaris Therapeutics in a research note on Wednesday, October 12th. They set a "sell" rating for the company. BTIG Research began coverage on Aclaris Therapeutics in a research note on Thursday, October 6th. They set a "buy" rating and a $32.00 price objective for the company. Stifel Nicolaus began coverage on Aclaris Therapeutics in a report on Tuesday, December 13th. They set a "buy" rating and a $29.00 target price on the stock. SVB Leerink reiterated an "outperform" rating on shares of Aclaris Therapeutics in a report on Tuesday, November 8th. Finally, The Goldman Sachs Group began coverage on Aclaris Therapeutics in a report on Thursday, December 1st. They set a "buy" rating and a $25.00 target price on the stock. One investment analyst has rated the stock with a sell rating and six have issued a buy rating to the company's stock. According to MarketBeat.com, Aclaris Therapeutics presently has an average rating of "Moderate Buy" and a consensus target price of $28.67.
多家券商近日對ACRS發表評論。StockNews.com在10月12日星期三的一份研究報告中開始報道Aclaris治療公司。他們為該公司設定了“賣出”評級。BTIG研究在10月6日星期四的一份研究報告中開始報道Aclaris治療公司。他們為該公司設定了“買入”評級和32.00美元的目標價。Stifel Nicolaus在12月13日星期二的一份報告中開始報道Aclaris治療公司。他們為該股設定了“買入”評級和29.00美元的目標價。SVB Leerink在11月8日(星期二)的一份報告中重申了對Aclaris治療公司股票的“跑贏大盤”評級。最後，高盛在12月1日星期四的一份報告中開始對Aclaris治療公司進行報道。他們為該股設定了“買入”評級和25.00美元的目標價。一名投資分析師對該股的評級為賣出，六名分析師對該公司股票的評級為買入。根據MarketBeat.com的數據，Aclaris治療公司目前的平均評級為“中等買入”，共識目標價為28.67美元。
Aclaris Therapeutics Stock Performance
Aclaris Treateutics股票表現
The company has a fifty day simple moving average of $16.26 and a two-hundred day simple moving average of $16.04.
該公司的50日簡單移動均線切入位16.26美元，200日簡單移動均線切入位16.04美元。
Insider Activity
內幕活動
In other news, insider Joseph Monahan sold 5,000 shares of the business's stock in a transaction dated Thursday, December 15th. The stock was sold at an average price of $15.88, for a total value of $79,400.00. Following the sale, the insider now directly owns 96,386 shares in the company, valued at $1,530,609.68. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. In related news, Director Neal Walker sold 25,000 shares of Aclaris Therapeutics stock in a transaction dated Tuesday, January 3rd. The stock was sold at an average price of $15.25, for a total value of $381,250.00. Following the sale, the director now owns 1,220,763 shares of the company's stock, valued at $18,616,635.75. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, insider Joseph Monahan sold 5,000 shares of Aclaris Therapeutics stock in a transaction dated Thursday, December 15th. The shares were sold at an average price of $15.88, for a total value of $79,400.00. Following the completion of the sale, the insider now directly owns 96,386 shares in the company, valued at approximately $1,530,609.68. The disclosure for this sale can be found here. Corporate insiders own 6.70% of the company's stock.
在其他新聞方面，內部人士約瑟夫·莫納漢在12月15日星期四的一筆交易中出售了5000股該公司股票。這隻股票的平均售價為15.88美元，總價值為79,400.00美元。出售後，這位內部人士現在直接擁有該公司96,386股，價值1,530,609.68美元。這筆交易是在提交給美國證券交易委員會的一份文件中披露的，該文件可通過美國證券交易委員會網站。相關新聞，董事尼爾·沃克在一筆日期為1月3日(星期二)的交易中出售了25,000股Aclaris治療公司的股票。股票以15.25美元的平均價格出售，總價值為381,250.00美元。交易完成後，董事現在擁有1220,763股公司股票，價值18,616,635.75美元。這筆交易是在提交給美國證券交易委員會的一份文件中披露的，該文件可通過此超鏈接。此外，內部人士約瑟夫·莫納漢在12月15日星期四的交易中出售了5,000股Aclaris治療公司的股票。這些股票的平均價格為15.88美元，總價值為79,400.00美元。出售完成後，該內部人士現在直接擁有該公司96,386股，價值約1,530,609.68美元。關於這次銷售的披露可以找到這裏。公司內部人士持有該公司6.70%的股份。
Institutional Trading of Aclaris Therapeutics
Aclaris Treeutics的機構交易
A number of hedge funds and other institutional investors have recently modified their holdings of the stock. Strs Ohio increased its position in Aclaris Therapeutics by 82.9% during the fourth quarter. Strs Ohio now owns 36,400 shares of the biotechnology company's stock worth $573,000 after buying an additional 16,500 shares during the last quarter. Bank of New York Mellon Corp increased its position in Aclaris Therapeutics by 15.7% during the third quarter. Bank of New York Mellon Corp now owns 233,882 shares of the biotechnology company's stock worth $3,682,000 after buying an additional 31,683 shares during the last quarter. Teachers Retirement System of The State of Kentucky acquired a new position in Aclaris Therapeutics during the third quarter worth approximately $850,000. California State Teachers Retirement System increased its position in Aclaris Therapeutics by 5.8% during the third quarter. California State Teachers Retirement System now owns 65,616 shares of the biotechnology company's stock worth $1,033,000 after buying an additional 3,618 shares during the last quarter. Finally, Balyasny Asset Management LLC acquired a new position in Aclaris Therapeutics during the third quarter worth approximately $1,670,000. Institutional investors and hedge funds own 95.33% of the company's stock.
一些對衝基金和其他機構投資者最近調整了對該股的持有量。第四季度，俄亥俄州STRS將其在Aclaris治療公司的地位增加了82.9%。STR俄亥俄州現在擁有這家生物技術公司36,400股票，價值573,000美元，在上個季度又購買了16,500股票。紐約梅隆銀行在第三季度將其在Aclaris治療公司的頭寸增加了15.7%。紐約梅隆銀行(Bank Of New York Mellon Corp)目前擁有233,882股這家生物技術公司的股票，價值3,682,000美元，此前該公司在上個季度又購買了31,683股。肯塔基州教師退休系統在第三季度獲得了Aclaris治療公司的一個新職位，價值約85萬美元。加利福尼亞州教師退休系統在第三季度將其在Aclaris治療公司的職位增加了5.8%。加州教師退休系統現在擁有這家生物技術公司65,616股股票，價值1,033,000美元，此前在上個季度又購買了3,618股。最後，Balyasny Asset Management LLC在第三季度收購了Aclaris治療公司的一個新頭寸，價值約167萬美元。機構投資者和對衝基金持有該公司95.33%的股票。
Aclaris Therapeutics Company Profile
Aclaris治療公司簡介
(Get Rating)
(獲取評級)
Aclaris Therapeutics, Inc operates a clinical-stage biopharmaceutical company, develops novel drug candidates for immune-inflammatory diseases in the United States. It operates through two segments: Therapeutics and Contract Research. The Therapeutics segment is involved in identifying and developing innovative therapies to address significant unmet needs for immuno-inflammatory diseases.
Aclaris治療公司經營着一家臨牀階段的生物製藥公司，在美國開發治療免疫性炎症性疾病的新型候選藥物。它通過兩個部門運作：治療和合同研究。治療部門參與確定和開發創新療法，以解決免疫炎症性疾病的重大未得到滿足的需求。
See Also
另請參閲
- Get a free copy of the StockNews.com research report on Aclaris Therapeutics (ACRS)
- Ride These Railroad Stocks for Growth and Income
- ASML Sees Demand For Chips Rallying This Year, Boosts Sales View
- KLA Corporation: Strength In A Troubled Semi-Market
- PCE Indicates Slowdown In Spending, Economy Weakens
- Microsoft's Comeback Is Now Underway
- 免費獲取StockNews.com關於Aclaris治療公司(ACRS)的研究報告
- 利用這些鐵路股票實現增長和收入
- ASML預計今年芯片需求回升，提振銷售觀點
- KLA公司：在動盪不安的半市場中站穩腳跟
- PCE表明支出放緩，經濟疲軟
- 微軟的捲土重來正在進行中
Receive News & Ratings for Aclaris Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aclaris Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
接受《Aclaris治療日報》的新聞和評級-在下面輸入您的電子郵件地址，通過MarketBeat.com的免費每日電子郵件時事通訊接收對Aclaris治療公司和相關公司的最新新聞和分析師評級的每日簡要摘要。